Marstacimab‑Hncq Suppliers & Bulk Manufacturers
Available Forms: injection (prefilled syringe)
Available Strengths: 150 mg/mL
Reference Brands: Hympavzi (USA)
Category: Plasma Products
Marstacimab-hncq is a human monoclonal IgG1 antibody that antagonizes the tissue factor pathway inhibitor (TFPI), thereby promoting thrombin generation and improving clot formation in patients with haemophilia A or B without inhibitors. It is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and adolescents (≥ 12 years) with haemophilia A without factor VIII inhibitors or haemophilia B without factor IX inhibitors. Marstacimab‑hncq is available in injection (prefilled syringe) and strengths such as 150 mg/mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Marstacimab‑hncq is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Marstacimab‑hncq can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Marstacimab-hncq is used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and adolescents with hemophilia A or B who do not have inhibitors to coagulation factors VIII or IX.
Marstacimab-hncq is made from a recombinant human monoclonal antibody that targets and inhibits tissue factor pathway inhibitor (TFPI), thereby enhancing the generation of thrombin and improving blood clotting.
The trade name of Marstacimab-hncq is Amtuvemo.
Marstacimab-hncq is developed and manufactured by Pfizer Inc.
The generic name is Marstacimab-hncq.
The brand name is Amtuvemo.
Marstacimab-hncq (Amtuvemo) is manufactured by Pfizer Inc., in the United States.
Related Products
Emicizumab‑Kxwh
Strength:
30 mg/mL, 60 mg/0.4 mL, 105 mg/0.7 mL
Form: Injection
Reference Brands: Hemlibra (USA/EU)
View Details
Concizumab-Mtci
Strength:
60 mg/1.5 mL, 150 mg/1.5 mL, 300 mg/3 mL
Form: Prefilled autoinjector
Reference Brands: Alhemo (USA/EU)
View Details
Fresh Frozen Plasma (Ffp) Powder For Reconstitution Or Liquid
Strength:
available in 200-250 mL units
Form: liquid units or lyophilized (freeze-dried) powder
Reference Brands: No specific brands
View Details
Plasma Protein Fraction (Ppf) Powder
Strength:
50 mL, 250 mL, or 500 mL
Form: Lyophilized Powder or Liquid
Reference Brands: Plasmanate (US), Octaplas LG, Biotest Plasma (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
